WuXi XDC Cayman Inc. (HKG:2268)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
41.15
-1.70 (-3.97%)
Apr 3, 2025, 4:08 PM HKT
126.85%
Market Cap 51.42B
Revenue (ttm) 4.31B
Net Income (ttm) 1.14B
Shares Out 1.20B
EPS (ttm) 0.88
PE Ratio 48.51
Forward PE 33.66
Dividend n/a
Ex-Dividend Date n/a
Volume 11,718,078
Average Volume 9,963,975
Open 41.60
Previous Close 42.85
Day's Range 39.65 - 42.55
52-Week Range 14.08 - 49.50
Beta n/a
RSI 52.54
Earnings Date Mar 26, 2025

About WuXi XDC Cayman

WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services. The company was founded in 2013 and is headquartered in Wuxi, China.... [Read more]

Sector Healthcare
Founded 2013
Employees 2,041
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2268
Full Company Profile

Financial Performance

In 2024, WuXi XDC Cayman's revenue was 4.05 billion, an increase of 90.80% compared to the previous year's 2.12 billion. Earnings were 1.07 billion, an increase of 277.24%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.